Non-small cell lung cancer in countries of Central and Southeastern Europe

diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group

Ales Ryška (Author), Rares Buiga (Author), Albena Fakirova (Author), Izidor Kern (Author), Włodzimierz Olszewski (Author), Lukas Plank (Author), Sven Seiwerth (Author), Erika Toth (Author), Eri Zivka (Author), Christiane Thallinger (Author), Christoph Zielinski (Author), Luka Brčić (Author)

Abstract

This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. Implications for Practice. This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.

Keywords

Central Europe;Southeastern Europe;reimbursement;

Data

Language:	English
Year of publishing:	2018
Typology:	1.01 - Original Scientific Article
Publisher:	AlphaMed Press
UDC:	616-006
COBISS:	2048460913
ISSN:	1549-490X
Views:	868
Downloads:	189
Average score:	0 (0 votes)
Metadata:

Other data

Secondary keywords:	Srednja Evropa;Jugovzhodna Evropa;povračilo stroškov;Carcinoma, non-small cell lung;Diagnosis;Economics;Europe;Molecular diagnostic techniques;Precision medicine;Nedrobnocelični karcinom pljuč;diagnostika;ekonomika;Evropa;Molekularne diagnostične tehnike;Personalizirana medicina;
Source comment:	Soavtor iz Slovenije: Izidor Kern; Nasl. z nasl. zaslona; Opis vira z dne 27. 3. 2019;
Pages:	str. e152-e158
Volume:	ǂVol. ǂ23
Issue:	ǂno. ǂ12
Chronology:	Dec. 2018
DOI:	10.1634/theoncologist.2018-0008
ID:	12143214